Cartesian Therapeutics, Inc. ( (RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases, with a unique approach that allows for repeated dosing without integrating into the cell’s genetic material. In its latest earnings report for the quarter ended September 30, 2025, Cartesian Therapeutics highlighted a significant net loss, while also reporting on its financial condition and strategic developments. Key financial metrics showed a decrease in cash and cash equivalents from $212.6 million at the end of 2024 to $143.4 million as of September 30, 2025, alongside a net loss of $35.9 million for the quarter. Despite these challenges, the company continues to invest heavily in research and development, with expenses rising to $13.8 million for the quarter. Looking ahead, Cartesian Therapeutics remains focused on advancing its product candidates through preclinical and clinical development, with management expressing confidence in the company’s ability to fund operations for at least the next 12 months.